Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 746-757

  Miller, Lesley Ann ^a   Burudpakdee, Chakkarin ^b   Zagar, Anthony ^a   Bhosle, Monali ^b   Reaney, Matthew ^a   Schabert, Vernon F ^b   Bruhn, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

Author keywords

Exenatide; Glucagon like peptide 1 (GLP 1) receptor agonists; Liraglutide; Type 2 diabetes

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE;

ADULT; AGED; ARTICLE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GERMANY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; VENOMS; YOUNG ADULT;

EID: 84862519826     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.679756     Document Type: Article

References (22)

1. World Health Organization. Diabetes Action Now. WHO and IDF, 2004. http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf. Accessed March 1, 2012
2. International Diabetes Federation and Federation of European Nurses in Diabetes. Diabetes - The Policy Puzzle: is Europe making progress? 2nd edn. IDF and FEND, 2008. http://www.idf.org/regions/europe/publications/diabetes-policy- audit. Accessed March 1, 2012
3. International Diabetes Federation. IDF Diabetes Atlas: prevalence estimates of diabetes mellitus (DM). 5th edn. IDF, 2011. http://www. diabetesatlas.org/content/prevalence-estimates-diabetes-mellitus-dm-2010. Accessed March 1, 2012
4. Hauner H, Bramlage P, Lö sch C, et al. Overweight, obesity and high waist circumference: regional differences in prevalence in primary medical care. Dtsch Arztebl Int 2008;105:827-33
5. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42 (Pubitemid 38101606)
6. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70 (Pubitemid 41751172)
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
8. Lind M, Jendle J, Torffvit O, et al. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41-6
9. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72
10. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9
11. Byetta-[package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2010
12. Victoza-[package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2011
13. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611
14. GLUCOPHAGE-[package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009
15. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100 (Pubitemid 40616618)
16. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35 (Pubitemid 39441462)
17. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91 (Pubitemid 40616617)
18. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
19. McGill JB. Selecting among ADA/EASD tier 1 and tier 2 treatment options. J Fam Pract 2009;58(9 Suppl Treating):S26-34
20. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-10
21. Ryder REJ, Thong KY, Cull ML, et al. The Association of British Clinical Diabetologists (ABCD) nationwise exenatide and liraglutide audits. Poster. Association of British Clinical Diabetologists Meeting. London, England. November 10-11, 2011
22. Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits. Abstract 00470. International Diabetes Federation World Diabetes congress. Dubai, United Arab Emirates. December 4-8, 2011